Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
NCT ID: NCT00985387
Last Updated: 2011-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1215 participants
OBSERVATIONAL
2009-08-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solifenacin treatment
Male and female OAB patients who were treated with solifenacin
Solifenacin
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solifenacin
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The question 3 score of the overactive bladder symptom score(OABSS)≥ 2 and the sum score of OABSS ≥ 3
* Symptoms of urinary urgency defined as a level of 1 to 2 in a 3-point Urgency Perception Scale (UPS)
Exclusion Criteria
* Symptomatic acute urinary tract infection (UTI)
* Diagnosed or suspected of interstitial cystitis
* Treatment with anticholinergic drugs for over 3 months within 12 months prior to the study
* Pregnant or nursing women
* Treatment within the 14 days before the study or expected to initiate treatment during the study with any anticholinergic drugs other than solifenacin or treatment for overactive bladder with other drugs
* Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Korea, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_CHAIR
Astellas Pharma Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bucheon-si, , South Korea
Bucheon-si, , South Korea
Busan, , South Korea
Busan, , South Korea
Busan, , South Korea
Busan, , South Korea
Chuncheon, , South Korea
Daegu, , South Korea
Daegu, , South Korea
Daegu, , South Korea
Daegu, , South Korea
Daejeon, , South Korea
Daejeon, , South Korea
Daejeon, , South Korea
Gangneung, , South Korea
Gumi, , South Korea
Gwangju, , South Korea
Gwangju, , South Korea
Gwangju, , South Korea
Gyongju, , South Korea
Hwasun, , South Korea
Iksan, , South Korea
Inchon, , South Korea
Inchon, , South Korea
Jeonju, , South Korea
Jeonju, , South Korea
Jeonju, , South Korea
Masan, , South Korea
Seongnam, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Seoul, , South Korea
Suwon, , South Korea
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPK-1
Identifier Type: -
Identifier Source: org_study_id